ISR - Isoray posts FQ3 revenue slide wider loss

Isoray (ISR) posted a slide in its fiscal third-quarter revenue, as the company dealt with weak performance from its core prostate brachytherapy business.Revenue for the third quarter declined 10% to $2.60M versus $2.88M last year, beating analysts' estimate by $0.19M.The company, however, highlighted that revenue increased 10% sequentially from the fiscal second quarter.The net loss for the three months ended March 31, 2021 was $0.75M, or ($0.01) per share versus a net loss of $0.55M, or ($0.01) per share last year.Cash, cash equivalents, and certificates of deposit at the end of the third quarter totaled $64.8M and the company had no long-term debt.Isoray shares up nearly 1% post-market.Previously (May 13): IsoRay EPS in-line, beats on revenue.

For further details see:

Isoray posts FQ3 revenue slide, wider loss